logo-loader
RNS
viewMidatech Pharma PLC

Midatech Pharma PLC - Publication of Annual Report

RNS Number : 5637R
Midatech Pharma PLC
30 June 2020
 

30 June 2020

Midatech Pharma PLC

 

("Midatech" or the "Company")

 

Publication of Annual Report

 

Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines announces that electronic copies of its Annual Report and Accounts for the year ended 31 December 2019 are now available from the Company's investor relations website at http://www.midatechpharma.com/.  Hard copies of the 2019 Annual Report and Accounts are expected to be posted to shareholders shortly.

 

For more information, please contact:

  Midatech Pharma PLC

  Stephen Stamp, CEO, CFO

  Tel: +44 (0)1235 888300

  www.midatechpharma.com

 

  Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

  Freddy Crossley, Emma Earl (Corporate Finance)

  James Stearns (Corporate Broking)

 

  Turner Pope Investments (TPI) Limited (Joint Broker)

  Andrew Thacker (Corporate Broking)

  Tel: +44(0)20 3657 0050

 

  IFC Advisory Limited (Financial PR and UK Investor Relations)

  Tim Metcalfe / Graham Herring

  Tel: +44 (0)20 3934 6630

  Email: [email protected]

 

  Edison Group (US Investor Relations)

  Joseph Green/ Laine Yonker

  Tel: (646) 653-7030/ 7035

  j[email protected]/[email protected]

 

 

About Midatech Pharma PLC

 

Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: MTP) is an R&D company focused on 'Making Medicines Better' by improving delivery of drugs in the body. The Company combines existing medications with its proprietary and innovative drug delivery technologies to provide compelling oncology and rare disease products that have the potential to powerfully impact the lives of patients undergoing treatment for life threatening diseases.

 

The Company has developed three in-house technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform:

 

 

·

Q-Sphera™ platform: a disruptive micro-technology used for sustained release to prolong and control the release of therapeutics over an extended period of time (from weeks to months).

 

·

MidaSolve™ platform: an innovative nano-technology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours.

 

 

·

MidaCore™ platform: a leading edge nano-technology used for targeting medications to sites of disease.

 

By improving biodelivery and biodistribution of approved existing molecules, Midatech's unique R&D has the potential to make medicines better, lower technical risks, accelerate regulatory approval and route to market, and provide newly patentable products. The platform nature of the technologies allows the potential to develop multiple drug assets rather than being reliant on a limited number of programmes.

 

Midatech's headquarters and R&D facility is in Cardiff, UK. For more information please visit www.midatechpharma.com.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ACSFZGFVZGDGGZM

Quick facts: Midatech Pharma PLC

Price: 43.6

Market: AIM
Market Cap: £26.4 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE